BSE - Delayed Quote INR

Supriya Lifescience Limited (SUPRIYA.BO)

663.25
+1.35
+(0.20%)
At close: May 13 at 3:29:02 PM GMT+5:30

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.
NameTitlePayExercisedYear Born
Dr. Satish Waman Wagh Founder, Executive Chairman & Whole Time Director 11.65M -- 1955
Ms. Smita Satish Wagh Whole-time Director 1.75M -- 1958
Dr. Saloni Satish Wagh Managing Director 1.81M -- 1990
Ms. Shivani Satish Wagh Joint Managing Director 1.81M -- 1991
Mr. Balasaheb Gulabrao Sawant Whole Time Director 632k -- 1964
Mr. Krishna Raghunathan Chief Financial Officer 3.34M -- --
Dr. Shireesh Bhalchandra Ambhaikar Technical Head 892k -- --
Dr. Sushanta Kumar Gouranga Mishra Chief Scientific Officer -- -- --
Ms. Prachi Sathe Company Secretary & Compliance Officer -- -- --
Dr. Prashant Baban Zate Head of Corporate Quality Assurance & Regulatory Affairs -- -- --

Supriya Lifescience Limited

207/208 Udyog Bhavan
Sonawala Road Goregoan (East)
Mumbai, 400063
India
91 22 4033 2727 https://www.supriyalifescience.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
448

Description

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, anti-malarial products, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, it also offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, the company is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessasion, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic, stem cell transplantation, and anti-migraine. The company was founded in 1987 and is headquartered in Mumbai, India.

Corporate Governance

Supriya Lifescience Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 28, 2025 at 10:59 AM UTC - May 29, 2025 at 12:00 PM UTC

Supriya Lifescience Limited Earnings Date

Recent Events

September 20, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers

NKGN NKGen Biotech, Inc.
0.2997
+11.00%
 
DWTX Dogwood Therapeutics, Inc.
4.8500
+1.46%
 
PLRZ Polyrizon Ltd.
0.0285
-91.86%
 
NCNA NuCana plc
0.0329
-17.75%